Modeling Outcome in Patients With Acquired Brain Injuries

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIstituto per la Ricerca e l'Innovazione Biomedica

About this trial

Acquired brain injury (ABI) is the leading cause of death and disability worldwide. The degree of severity varies according to a combination of numerous demographics, etiological, clinical, cognitive, behavioral, psychosocial and environmental factors, which can interfere with the effectiveness of rehabilitation interventions and, therefore, with the final outcome.

The most important goal of the modern clinic is to predict in time the progression of possible recovery after the brain injury event in order to provide more effective treatment, but the high heterogeneity and clinical variability and the unpredictability of the onset of comorbidities makes this a hard target to reach.

In recent years, artificial intelligence algorithms have been applied to more precisely define the role of critical variables that can help clinical practice to predict the final outcome. The classical approach of these algorithms provides only probabilistic values on the final outcome, without considering the typology of clinical interventions and overall complications that may appear throughout the hospitalization period.

The objective of this multicentric study is to define a new statistical approach that can describe the dynamics of individual clinical changes occuring during the inpatient intensive rehabilitation care period. The proposed approach combines a principal component analysis (PCA) for dimension reduction (capturing the maximum amount of information and reducing the dimensionality problem) and a nonlinear mathematical modeling for describing the evolution of the clinical course in terms of the resulting new PCA dimensions. By using this approach, we may determine the individual patient's temporal trajectories while examining particular clinical factors. The secondary objective of this study is to validate a new version of the Early Rehabilitation Barthel Index (ERBI), a well-known clinical scale used to measure functional changes in patients with severe acquired brain injury.

Eligibility criteria

Qualifiers

patients with clinical diagnosis of severe acquired brain injury of different etiology (traumatic, hemorrhagic vascular,ischemic vascular, anoxic, infectious, other etiology

interval since the acute occurrence that led to the clinical condition of ≤3 months duration

age of 18 years or older

informed consent signed by family member/caregiver/supporting caregiver

Disqualifiers

Positive remote medical history of pre-existing disabling neurological or orthopedic conditions and psychiatric disorders

Trial design

Treatments tested in this trial

  • Data collection

Treatment groups

190 Participants
are divided into 1 treatment group

Sponsors and collaborators

Istituto per la Ricerca e l'Innovazione Biomedica

Lead sponsor

Istituto S.Anna Crotone

Collaborator

IRCCS Centro Neurolesi Bonino Pulejo

Collaborator

Centro Cardinal Ferrari, Fontanellato, Parma

Collaborator

Fondazione Istituto G. Giglio, Cefalù (PA)

Collaborator

Habilita Istituto di Neuroriabilitazione, Zingonia (BG)

Collaborator

Casa Sollievo della Sofferenza IRCCS

Collaborator

IRCCS Istituto delle Scienze Neurologiche di Bologna

Collaborator

IRCCS Sacro Cuore Don Calabria di Negrar

Collaborator

Fondazione Salvatore Maugeri

Collaborator

Istituti Clinici Zucchi

Collaborator

Istituto Clinico Humanitas

Collaborator

Istituto Medicina Fisica E Riabilitazione Gervasutta, Udine

Collaborator

Montecatone Rehabilitation Institute S.p.A.

Collaborator

Ospedale Di Riabilitazione Fondazione Santa Lucia, Roma

Collaborator

Ospedale San Giovanni Battista, Foligno (PG)

Collaborator

Ospedale Ss. Trinità Di Fossano, Cuneo

Collaborator

Fondazione Don Carlo Gnocchi Onlus

Collaborator